Pipeline

ETX Pharma, Inc is developing orally administered drugs candidates with highly favorable safety profiles to treat the underlying causes of several major Gastrointestinal  diseases

ETX-101

Diabetes’s-associated gastroparesis and idiopathic gastroparesis (of unknown cause) are neuropathies of the stomach muscles exhibiting loss of nitric oxide signaling “relax message” that prevent normal emptying of the stomach. This condition seriously reduces the patient’s quality of life and increases both morbidity and mortality

  • ETX-101 is the only drug currently in development that restores native nitric oxide signaling and should enjoy rapid adoption in this underserved indication
  • ETX-101 is presently manufactured as a tablet ready for Phase 2a trials in 2018, a potential early value inflection point

ETX-202

Diabetes’s-associated gastroparesis and idiopathic gastroparesis (of unknown cause) are neuropathies of the stomach muscles exhibiting loss of nitric oxide signaling “relax message” that prevent normal emptying of the stomach. This condition seriously reduces the patient’s quality of life and increases both morbidity and mortality

  • ETX-101 is the only drug currently in development that restores native nitric oxide signaling and should enjoy rapid adoption in this underserved indication
  • ETX-101 is presently manufactured as a tablet ready for Phase 2a trials in 2018, a potential early value inflection point

ETX-301

Diabetes’s-associated gastroparesis and idiopathic gastroparesis (of unknown cause) are neuropathies of the stomach muscles exhibiting loss of nitric oxide signaling “relax message” that prevent normal emptying of the stomach. This condition seriously reduces the patient’s quality of life and increases both morbidity and mortality

  • ETX-101 is the only drug currently in development that restores native nitric oxide signaling and should enjoy rapid adoption in this underserved indication
  • ETX-101 is presently manufactured as a tablet ready for Phase 2a trials in 2018, a potential early value inflection point